Literature DB >> 19258946

Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy.

Liliana Mereu1, Saverio Tateo, Catherine Klersy, Eva Martinotti Gabellotti, Franco Polatti.   

Abstract

UNLABELLED: The prevalence of venous thromboembolism (VTE) in ovarian cancer during first-line chemotherapy (CHT) ranges between 6.4% and 10.6%. Identification of the susceptible population is crucial for effective thromboprophylaxis.
METHODS: We performed a retrospective study of all our patients with epithelial ovarian cancer who underwent ambulatory first-line CHT between 1990 and 2004. Data were collected regarding age, body mass index (BMI), previous deep vein thrombosis, pulmonary embolism (PE), menopause status, FIGO stage, grade, histology, type of surgery, residual disease, and CHT. Univariable and multivariable regression analyses were performed to assess independent prognostic factors for VTE/PE to calculate a prognostic index (PI).
RESULTS: Of 203 patients, 16 (7.8%) had symptomatic VTE: 15 deep vein thrombosis and 1 PE. Multivariable regression analysis found that age (P = 0.01), BMI (P = 0.01), and stage (P = 0.05) were independent prognostic factors for VTE. Age, BMI, and stage were used to calculate the PI: 0.285 x age + 0.555 x BMI + 1.110 x stage. The PI was dichotomized according to its median cutoff (5.8) to define a low (3.8% at 6 months) and a high (11.3%) VTE incidence group.
CONCLUSIONS: Age, BMI, and stage permit to identify ovarian cancer patients with a high risk in developing symptomatic VTE during CHT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258946     DOI: 10.1111/IGJ.0b013e318199035e

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis.

Authors:  Shinichi Komiyama; Masaru Nagashima; Tomoko Taniguchi; Takayuki Rikitake; Mineto Morita
Journal:  Clin Drug Investig       Date:  2019-04       Impact factor: 2.859

2.  Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab.

Authors:  Anna Kuk; Magdalena Magnowska; Wiktor Suchy; Joanna Swierczynska; Mikolaj Piotr Zaborowski; Michal Gaca; Ewa Nowak-Markwitz
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

3.  The prevalence, risk factors, and prognostic value of venous thromboembolism in ovarian cancer patients receiving chemotherapy: a systematic review and meta-analysis.

Authors:  Lu Ye; Li Cai; Yonghui Fu; Debao Zhuang; Xiaoqing Hu; Youkun Jie
Journal:  World J Surg Oncol       Date:  2021-01-13       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.